Research
Hormonal
Tirzepatide was recently approved for the management of obesity.
Tirzepatide can be considered as a treatment option for obesity management.
StrongSupportsmedium confidence
A novel dual agonist of Glucose-dependent insulinotropic peptide (GIP) and Glucagon-like peptide -1 (GLP- 1) receptors, Tirzepatide, was recently approved for the management of obesity.
Why this rating
The claim is based on the approval status of a drug.
Source
A New Drug for Obesity: Tirzepatide
Jaspreet Kaur Sidhu et al. · Endocrine Metabolic & Immune Disorders - Drug Targets · 2024
DOI 10.2174/0118715303319530240703111013
otherCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →